BioRelix, Inc. and Dalton Medicinal Chemistry Partners Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

November 13, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW HAVEN, CT, and TORONTO, Nov. 13 /CNW/ - BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.

Twitter
LinkedIn
Facebook
Email
Print

Alliances